Consistent with previously well documented role for the Bcr-Abl-SKP2-p27 axis in leukemogenesis and CML progression, we found IM treatment dose-dependently reduced SKP2 protein levels and increased p27 protein levels in KBM5 cells but less so in KBM5-T315I cells (Fig. 1b). Here, SKP2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.